Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Astellas Proposes Acquisition to CV Therapeutics
February 2, 2009
- JIRA to Demand Digital X-Ray Imaging Fee
February 2, 2009
- Financial Crisis Offers Opportunity for Cash-Rich Biopharma Companies: BCG
February 2, 2009
- MEDICAL DEVICE NEWS IN BRIEF
February 2, 2009
- Hisamitsu to Comarket Fosamac with Banyu
February 2, 2009
- SELF-MEDICATION NEWS IN BRIEF
February 2, 2009
- Wholesalers Have Been Driven Over the Edge: Mr Kimura
February 2, 2009
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
February 2, 2009
- BUSINESS NEWS IN BRIEF
February 2, 2009
- Takeda to Face Critical Test in Next 1-2 Years: Mr Hasegawa
February 2, 2009
- 4 New Drugs from Novartis Approved at the Same Time
February 2, 2009
- 79 Unapproved APIs Used in 32% of Med. Institutions
February 2, 2009
- Makers Should Provide Information to Enhance the Value of Their Products: Mr Kinoshita
February 2, 2009
- Early Identification of Biomarkers Important in Developing Molecular-Targeted Drugs
February 2, 2009
- REGULATORY NEWS IN BRIEF
February 2, 2009
- Daiichi Sankyo to Apply for Anti-Flu Drug in 2009
February 2, 2009
- Statistics
February 2, 2009
- R&D NEWS IN BRIEF
February 2, 2009
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
January 26, 2009
- REGULATORY NEWS IN BRIEF
January 26, 2009
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…